Hospira buyout is a shot in the arm for Pfizer’s biosimilars
Thursday, February 12, 2015 - 08:40
in Mathematics & Economics
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt